Canvas Medical vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Modern cloud-native EHR for direct primary care and value-based care organizations; API-first architecture replacing legacy systems competing with athenahealth and Elation Health.
About
Canvas Medical is a cloud-native electronic health record (EHR) platform designed specifically for modern primary care practices — combining clinical documentation (notes, orders, prescriptions), care management (population health tracking, chronic disease programs, care gap identification), billing and revenue cycle, and patient communication in an integrated system built on a contemporary technical architecture. Founded in 2015 in San Francisco, Canvas Medical targets independent primary care practices, direct primary care (DPC) practices, and value-based care organizations frustrated with legacy EHR systems.\n\nCanvas Medical's technical approach differs from legacy EHRs (Epic, athenahealth, eClinicalWorks) which were built in the early 2000s — Canvas uses a modern, API-first architecture that makes integration with third-party tools straightforward, and its workflow design reflects current clinical practice patterns rather than 1990s paper-chart workflows. The platform is particularly popular with DPC (direct primary care) practices that operate on membership subscription models, where the EHR needs to support high-touch patient communication and proactive care rather than just fee-for-service billing. Canvas also serves value-based care organizations where population health management tools matter.\n\nIn 2025, Canvas Medical competes with athenahealth, Modernizing Medicine, Elation Health, and DrChrono for ambulatory EHR market share in the primary care segment. The EHR market is mature but experiencing disruption pressure as smaller, newer entrants offer more modern experiences to independent practices that Legacy systems with dated UX can't match. The Canvas SDK allows developers to build custom workflow integrations, positioning Canvas as a platform rather than a closed system. The 2025 strategy focuses on growing with DSC and value-based care organizations scaling their primary care networks, deepening AI-powered clinical documentation (ambient note generation), and expanding the developer ecosystem built on Canvas's open API.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.